Xu, E., Xie, Y
[313][314][315][316] Antibodies to liraglutide were found in 4% to 13% of subjects and did not appear to have any significant effect on the HgA1c-lowering efficacy of liraglutide.[317][318][319] As described above, DPP-IV inhibitors are compounds that increase the concentration of endogenous incretins, including GLP-1, by limiting the proteolytic cleavage by DPP-IV
By combining GLP-1 therapy with biologically personalized support, Digbi Health achieves significant reductions in GLP-1 adverse effects, thereby improving adherence and weight loss outcomes, and further extending the medical savings demonstrated in the claims analysis
Helmstdter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, Pawelke F, Kus K, Krller-Schn S, Oelze M